News summary
[Fu 'an Pharmaceuticalboxingpunchmachine: The subsidiary received the approval notice for the supplementary application for granisetron hydrochloride tablets] Securities Times e Company News, Fu 'an Pharmaceutical (300194) announced on the evening of May 22 that its wholly-owned subsidiary Tianheng Pharmaceutical recently received the National Drug Administration issued Granisetron Hydrochloride Tabletsboxingpunchmachine...
Newsletter text
[Fu 'an Pharmaceutical: The subsidiary received the approval notice for the supplementary application for granisetron hydrochloride tablets] Securities Times e Company News, Fu' an Pharmaceutical (300194) announced on the evening of May 22 that its wholly-owned subsidiary Tianheng Pharmaceutical has recently received the approval notice for the supplementary application for granisetron hydrochloride tablets issued by the State Food and Drug Administration. Granisetron hydrochloride tablets are mainly used for nausea and vomiting caused by radiotherapy and cytotoxic chemotherapy. Up to now, Tianheng Pharmaceutical's product is the first in China to pass the consistency evaluation or be deemed to have passed the consistency evaluation.